Recommendation of the President – Lecigon (levodopa + carbidopa + entacapone)
On 16 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 5/2026 on the reimbursement of the medicinal product Lecigon (levodopa + carbidopa + entacapone) under the B.90 drug program. “Treatment of motor disorders in advanced Parkinson’s disease (ICD-10: G.20)”